甲状腺乳头状癌合并桥本甲状腺炎肿瘤微环境中相关趋化因子的临床意义  

Clinical Chemokines in Papillary Thyroid Carcinoma Combined with Hashimoto's Thyroiditis

作　　者：乔琳舒 邵圣赞 戴天 吕恬 葛明华 QIAO Linshu;SHAO Shengzan;DAI Tian;LYU Tian;GE Minghua(School of Pharmacy,Hangzhou Normal University,Hangzhou 311121,China;Department of Head and Neck Surgery,Center of Otolaryngology-Head and Nech Surgery,Zhejiang Provincial People's Hospital(People's Hospital of Hangzhou Medical College),Hangzhou 310014,China;Zhejiang Chinese Medical University,Hangzhou 310053,China;Zhejiang Key Laboratory of Precision Medicine Research on Head&Neck Cancer,Hangzhou 310014,China;Zhejiang Provincial Clinical Research Center for Head and Neck Malignant Tumor,Hangzhou 310014,China)

机构地区：[1]杭州师范大学药学院,浙江杭州311121 [2]浙江省人民医院(杭州医学院附属人民医院)头颈外科,耳鼻咽喉-头颈外科中心,浙江杭州310014 [3]浙江中医药大学,浙江杭州310053 [4]浙江省头颈肿瘤精准医学研究重点实验室,浙江杭州310014 [5]浙江省头颈部恶性肿瘤临床医学研究中心,浙江杭州310014

出　　处：《肿瘤学杂志》2025年第2期100-107,共8页Journal of Chinese Oncology

基　　金：国家自然科学基金青年项目(82103027)。

摘　　要：[目的]探讨甲状腺乳头状癌(papillary thyroid carcinoma,PTC)合并桥本甲状腺炎(Hashimoto’s thyroiditis,HT)肿瘤微环境中相关趋化因子的临床意义。[方法]收集2023年5—10月浙江省人民医院收治的60例PTC患者病理组织切片,将其分为无淋巴结转移(no lymph node metastasis,NLNM)PTC合并HT组、NLNM PTC不合并HT组、淋巴结转移(lymph node metastasis,LNM)PTC合并HT组以及LNM PTC不合并HT组。比较4组患者的发病年龄、性别、肿瘤大小、临床病理特点等临床资料。前期采用人源趋化因子芯片QAH-CHE-1进行筛选PTC合并HT和不合并HT患者间有差异的趋化因子(CCL21、CCL19、CCL8、CXCL5),再利用免疫组化的方法检测上述4组患者PTC肿瘤组织中趋化因子CCL21、CCL19、CCL8和CXCL5的表达情况。[结果]PTC患者中,HT较易发生于女性。PTC合并HT组较PTC不合并HT组肿瘤直径更大[(9.70±5.23)mm vs(9.43±2.48)mm,P=0.013]。免疫组化结果显示,CCL21、CCL19、CCL8和CXCL5在PTC合并HT组的强阳性(++++)表达率均显著高于PTC不合并HT组(P均<0.05);有淋巴结转移的PTC合并HT患者各趋化因子的阳性表达率与无淋巴结转移患者差异均无统计学意义(P均>0.05)。[结论]趋化因子CCL21、CCL19、CCL8和CXCL5可能与HT慢性刺激在PTC的发生及进展中所承担的角色及潜在分子机制相关。[Objective]To investigate the clinical significance of tumor microenvironment-related chemokines in papillary thyroid carcinoma(PTC)combined with Hashimoto's thyroiditis(HT).[Methods]Sixty patients with PTC admitted in Zhejiang Provincial Hospital from May to October 2023 were enrolled,and patients were divided into(no lymph node metastasis,NLNM)PTC with HT group,NLNM PTC without HT group,lymph node metastatis(LNM)PTC with HT group and LNM PTC without HT group.The age,gender,tumor size and clinicopathological characteristics of 4 groups were compared.Human chemokine chip QAH-CHE-1 was used for screening of differentially expressed chemokine(CCL21,CCL19,CCL8 and CXCL5)in tissue sections between PTC patients with and without HT.The protein expressions of CCL21,CCL19,CCL8 and CXCL5 in the PTC tissues were detected by immunohistochemistry.[Results]Among PTC patients,HT was more likely to occur in women.The tumor diameter was larger in the PTC with HT group than that in the PTC without HT group[(9.70±5.23)mm vs(9.43±2.48)mm,P=0.013].The results of immunohistochemistry showed that the strong positive(++++)expression rates of CCL21,CCL19,CCL8 and CXCL5 in the PTC with HT group were significantly higher than those in the PTC without HT group(all P<0.05),and there was no significant difference in the positive expression rates of chemokines between patients with LNM and without LNM(all P>0.05).[Conclusion]Chemokines CCL21,CCL19,CCL8 and CXCL5 may be the potential molecular mechanism related to the role of HT in the development of PTC.

关 键 词：甲状腺乳头状癌 淋巴结转移 PTC 肿瘤微环境 桥本甲状腺炎 临床意义 

分 类 号：R736.1[医药卫生—肿瘤]